JENNIFER LADEVEZE: Open Payments
NPI 1629585435 · VIRGINIA BEACH, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,115 in 81 payments from 18 companies in 2025. Trend: 2023 $195 · 2024 $816 · 2025 $2,115
Food & beverage: $2,115
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $402 |
| Lilly USA, LLC | 2 | $249 |
| ABBVIE INC. | 10 | $218 |
| PFIZER INC. | 8 | $152 |
| Otsuka America Pharmaceutical, Inc. | 6 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $148 |
| Corcept Therapeutics | 2 | $144 |
| AstraZeneca Pharmaceuticals LP | 8 | $137 |
| Novartis Pharmaceuticals Corporation | 6 | $106 |
| Lundbeck LLC | 5 | $75 |
Products named: REXULTI, VRAYLAR, Ozempic, CAPLYTA, Korlym, Wegovy, MOUNJARO, ZEPBOUND.
Industry payments across VA — which companies pay providers there.
